Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLNEW: CTA313 in Active Autoimmune Diseases
NCT07783269Phase 1Not yet recruiting
- Sponsor
- Imviva
- Start
- Dec 2026
- Primary completion
- Jun 2029
01
Overview
Phase 1, open-label, single-arm trial of CTA313 in systemic lupus erythematosus (SLE), multiple sclerosis (MS) and Autoimmune Encephalitis (AE), sponsored by Imviva. Primary endpoints: Safety Profile at 24 months and Recommended Phase 2 Dose Determination at 24 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CTA313
03
Conditions
systemic lupus erythematosus (SLE)multiple sclerosis (MS)Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT07783269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783269.